Medicis Pharmaceutical Corp (NYSE:MRX)
| CAPS Rating |
|
|---|---|
| Open | $33.42 |
| Previous Close | $33.74 |
| Daily Range | $33.17 - $33.60 |
| 52-Week Range | $25.15 - $40.51 |
| Market Cap | $2.12B |
| P/E Ratio | 25.00 |
| Dividend (Yield) | 0.32 (0.70%) |
| Volume | 680,802 |
| Average Daily Volume | 0 |
MRX
VS S&P 500 (SPY)
How do you think MRX will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
MRX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
MRX News and Commentary
- Allergan Looks to Benefit from Botox Demand, Business Mix – Minyanville
- Solta's LIPOSONIX Reaches the U.S. - Analyst Blog – NASDAQ
- Solta Medical Backs 4Q View - Analyst Blog – NASDAQ
- Medicis Cuts Fourth Quarter View - Analyst Blog – NASDAQ
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- US Stock Futures: HOT STOCKS TO WATCH – SmartMoney
- Lupin Gets US OK For Several Strengths Of Generic Acne Treatment – SmartMoney
- Magic Formula Investing Weekly Roundu 11/27/2011 – Blog at The Motley Fool
- Medicis Eyes Graceway Pharma - Analyst Blog – NASDAQ
- Applications Given Early Antitrust Clearance – SmartMoney
- Medicis Pharmaceutical Earnings Preview – The Motley Fool
- This Just In: Upgrades and Downgrades – The Motley Fool
- Don't Get Too Worked Up Over Allergan's Earnings – The Motley Fool
- 5 Warning Signs for IPOs – The Motley Fool
- Don't Get Too Worked Up Over Valeant Pharmaceuticals' Latest Numbers – The Motley Fool
- The 20 Fastest Growers in Pharma – The Motley Fool
- Investing 101: The Most Undervalued Golden Cross Breakout Stocks – The Motley Fool
- Death of drug company exec's girlfriend ruled suicide – Reuters
- Investing 101: Rallying Health Care Stocks Being Snapped Up by the Smart Money – The Motley Fool
- Is Botox Really Recession-Resistant? – The Motley Fool
RSS Headlines
Fool UK
